David Weinreich

As Global Head of R&D and Chief Medical Officer, David Weinreich leads Research and Development for the Healthcare business sector of Merck, including Medical Affairs. He is a member of the Healthcare Executive Committee.

David joined Merck in September 2025 from Foresite Labs & Foresite Capital Management LLC, where he served as an Operating Partner and Senior Advisor. His previous experience includes: Executive Vice President, Head, Global Clinical Development at Regeneron; Corporate Senior Vice President, Head, Global Development Specialty Medicine at Bayer; and Executive Medical Director, Global Product Area Leader (Angiogenesis) at Amgen. He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career. In addition, David has founded multiple companies and served as a venture capitalist, board member, and biotech CEO.

David brings to Merck an exceptional record of success in leading early-stage and late-stage development, with leadership responsibility in achieving approvals across the globe for multiple therapies and indications. He has extensive experience in shaping R&D strategies that deliver meaningful value to patients and drive sustainable growth for future innovation investments. He also has effectively managed large and complex pipelines and global R&D teams.

David’s education includes an International Executive MBA from the McDonough School of Business, Georgetown University. He earned a Doctorate of Medicine from Boston University School of Medicine and A Bachelor of Science in Computer Engineering from Columbia University.